{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:44:46Z","timestamp":1793414686548,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Muscarinic agonists represent a new class of treatments for psychosis with a mechanism distinct from typical and atypical antipsychotics. The muscarinic subtype M\n                    <jats:sub>4<\/jats:sub>\n                    has been proposed as the primary mediator of efficacy but results from recent clinical trials with M\n                    <jats:sub>4<\/jats:sub>\n                    -selective compounds have drawn this hypothesis into question. Instead, activation of both M\n                    <jats:sub>1<\/jats:sub>\n                    and M\n                    <jats:sub>4<\/jats:sub>\n                    receptor subtypes may be required for robust treatment effects. Here, we characterize the clinical-stage muscarinic agonist ML-007 in preclinical models and explore its therapeutic potential for treating psychosis in schizophrenia and Alzheimer\u2019s disease. ML-007 is a potent brain-penetrant agonist at both M\n                    <jats:sub>1<\/jats:sub>\n                    and M\n                    <jats:sub>4<\/jats:sub>\n                    muscarinic receptors that has demonstrated compelling efficacy across a range of preclinical models of psychosis in schizophrenia including amphetamine-induced hyperlocomotion, PCP-induced hyperlocomotion, and conditioned avoidance response. Moreover, ML-007 is approximately ten-fold more potent than the comparator xanomeline in all animal models. Dose-response experiments in M\n                    <jats:sub>1<\/jats:sub>\n                    and M\n                    <jats:sub>4<\/jats:sub>\n                    knockout mice reveal that the efficacy of ML-007 is dependent on both M\n                    <jats:sub>1<\/jats:sub>\n                    and M\n                    <jats:sub>4<\/jats:sub>\n                    receptors. Taken together, our data suggest that both M\n                    <jats:sub>1<\/jats:sub>\n                    and M\n                    <jats:sub>4<\/jats:sub>\n                    receptors contribute to the potent efficacy of ML-007 in preclinical rodent models of psychosis.\n                  <\/jats:p>","DOI":"10.1038\/s41386-025-02256-3","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:35:26Z","timestamp":1759592126000},"page":"840-845","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Preclinical efficacy of the muscarinic agonist ML-007 in psychosis models depends on both M1 and M4 receptors"],"prefix":"10.1038","volume":"51","author":[{"given":"Susmita","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maritza","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zane C.","family":"Norville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly R.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatol C.","family":"Kreitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,4]]},"reference":[{"key":"2256_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/0024-3205(93)90300-R","volume":"52","author":"AI Levey","year":"1993","unstructured":"Levey AI. Immunological localization of M1-M5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci. 1993;52:441\u20138.","journal-title":"Life Sci"},{"key":"2256_CR2","doi-asserted-by":"publisher","first-page":"10483","DOI":"10.1073\/pnas.96.18.10483","volume":"96","author":"J Gomeza","year":"1999","unstructured":"Gomeza J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodkin J, et al. Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M4 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci. 1999;96:10483\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"2256_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1021\/acsmedchemlett.6b00461","volume":"8","author":"MR Wood","year":"2017","unstructured":"Wood MR, Noetzel MJ, Melancon BJ, Poslusney MS, Nance KD, Hurtado MA, et al. Discovery of VU0467485\/AZ13713945: An M4 PAM evaluated as a preclinical candidate for the treatment of schizophrenia. ACS Med Chem Lett. 2017;8:233\u20138.","journal-title":"ACS Med Chem Lett"},{"key":"2256_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neuropharm.2017.06.010","volume":"123","author":"MW Wood","year":"2017","unstructured":"Wood MW, Martino G, Coupal M, Lindberg M, Schroeder P, Santhakumar V, et al. Broad analgesic activity of a novel, selective M1 agonist. Neuropharmacology. 2017;123:233\u201341.","journal-title":"Neuropharmacology"},{"key":"2256_CR5","first-page":"183","volume":"10","author":"DJ Foster","year":"2014","unstructured":"Foster DJ, Choi DL, Conn PJ, Rook JM. Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer\u2019s disease and schizophrenia. Neuropsychiatr Dis Treat. 2014;10:183\u201391.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2256_CR6","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/nn1972","volume":"10","author":"W Shen","year":"2007","unstructured":"Shen W, Tian X, Day M, Ulrich S, Tkatch T, Nathanson NM, et al. Cholinergic modulation of Kir2 channels selectively elevates dendritic excitability in striatopallidal neurons. Nat Neurosci. 2007;10:1458\u201366.","journal-title":"Nat Neurosci"},{"key":"2256_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0022-510X(77)90073-9","volume":"34","author":"EK Perry","year":"1977","unstructured":"Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci. 1977;34:247\u201365.","journal-title":"J Neurol Sci"},{"key":"2256_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/brain\/99.3.459","volume":"99","author":"DM Bowen","year":"1976","unstructured":"Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain. 1976;99:459\u201396.","journal-title":"Brain"},{"key":"2256_CR9","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","volume":"308","author":"P Davies","year":"1976","unstructured":"Davies P. Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer\u2019s disease. Lancet. 1976;308:1403.","journal-title":"Lancet"},{"key":"2256_CR10","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel H, Mesulam M-M, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain. 2018;141:1917\u201333.","journal-title":"Brain"},{"key":"2256_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","volume":"54","author":"NC Bodick","year":"1997","unstructured":"Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997;54:465\u201373.","journal-title":"Arch Neurol"},{"key":"2256_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0920-9964(99)00138-3","volume":"42","author":"HE Shannon","year":"2000","unstructured":"Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MDB, et al. Xanomeline, an M1\/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res. 2000;42:249\u201359.","journal-title":"Schizophr Res"},{"key":"2256_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2174\/1568007024606249","volume":"1","author":"F Bymaster","year":"2002","unstructured":"Bymaster F, Felder C, Ahmed S, McKinzie D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Target -CNS Neurol Disord. 2002;1:163\u201381.","journal-title":"Curr Drug Target -CNS Neurol Disord"},{"key":"2256_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1023\/A:1022844517200","volume":"28","author":"FP Bymaster","year":"2003","unstructured":"Bymaster FP, McKinzie DL, Felder CC, Wess J. Use of M1\u2013M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res. 2003;28:437\u201342.","journal-title":"Neurochem Res"},{"key":"2256_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.trci.2018.03.004","volume":"4","author":"T Voss","year":"2018","unstructured":"Voss T, Li J, Cummings J, Farlow M, Assaid C, Froman S, et al. Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer\u2019s disease. Alzheimer\u2019s Dement: Transl Res Clin Inter. 2018;4:173\u201381.","journal-title":"Alzheimer\u2019s Dement: Transl Res Clin Inter"},{"key":"2256_CR16","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00213-023-06362-2","volume":"240","author":"A Breier","year":"2023","unstructured":"Breier A, Brannan SK, Paul SM, Miller AC. Evidence of trospium\u2019s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results. Psychopharmacology. 2023;240:1191\u20138.","journal-title":"Psychopharmacology"},{"key":"2256_CR17","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1016\/S0140-6736(22)01990-0","volume":"400","author":"JH Krystal","year":"2023","unstructured":"Krystal JH, Kane JM, Correll CU, Walling DP, Leoni M, Duvvuri S, et al. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet. 2023;400:2210\u201320.","journal-title":"Lancet"},{"key":"2256_CR18","unstructured":"Kuntz L. Emraclidine for schizophrenia fails to meet primary endpoints in phase 2 EMPOWER trials. Psychiatric Times. Nov. 11 2024. https:\/\/www.psychiatrictimes.com\/view\/emraclidine-for-schizophrenia-fails-to-meet-primary-endpoints-in-phase-2-empower-trials."},{"key":"2256_CR19","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1089\/genedge.6.01.138","volume":"6","author":"A Philippidis","year":"2024","unstructured":"Philippidis A. StockWatch: neurocrine tumbles as schizophrenia data disappoints. GEN Edge. 2024;6:721\u20135.","journal-title":"GEN Edge"},{"key":"2256_CR20","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/0143-4160(93)90091-J","volume":"14","author":"D Button","year":"1993","unstructured":"Button D, Brownstein M. Aequorin-expressing mammalian cell lines used to report Ca2+ mobilization. Cell Calcium. 1993;14:663\u201371.","journal-title":"Cell Calcium"},{"key":"2256_CR21","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1124\/dmd.105.008201","volume":"34","author":"X Liu","year":"2006","unstructured":"Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, et al. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos. 2006;34:1443\u20137.","journal-title":"Drug Metab Dispos"},{"key":"2256_CR22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1001\/archpsyc.1972.01750260021004","volume":"27","author":"SH Snyder","year":"1972","unstructured":"Snyder SH. Catecholamines in the brain as mediators of amphetamine psychosis. Arch Gen Psychiatry. 1972;27:169\u201379.","journal-title":"Arch Gen Psychiatry"},{"key":"2256_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/npp.2011.181","volume":"37","author":"B Moghaddam","year":"2012","unstructured":"Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37:4\u201315.","journal-title":"Neuropsychopharmacology"},{"key":"2256_CR24","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2174\/138161210790170085","volume":"16","author":"M-L Wadenberg","year":"2010","unstructured":"Wadenberg M-L. Conditioned avoidance response in the development of new antipsychotics. Curr Pharm Des. 2010;16:358\u201370.","journal-title":"Curr Pharm Des"},{"key":"2256_CR25","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nature09159","volume":"466","author":"AV Kravitz","year":"2010","unstructured":"Kravitz AV, Freeze BS, Parker PRL, Kay K, Thwin MT, Deisseroth K, et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature. 2010;466:622\u20136.","journal-title":"Nature"},{"key":"2256_CR26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11095-022-03172-7","volume":"39","author":"SG Summerfield","year":"2022","unstructured":"Summerfield SG, Yates JWT, Fairman DA. Free drug theory \u2013 no longer just a hypothesis?. Pharm Res. 2022;39:213\u201322.","journal-title":"Pharm Res"},{"key":"2256_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ejphar.2008.12.020","volume":"603","author":"ML Woolley","year":"2009","unstructured":"Woolley ML, Carter HJ, Gartlon JE, Watson JM, Dawson LA. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice. Eur J Pharm. 2009;603:147\u20139.","journal-title":"Eur J Pharm"},{"key":"2256_CR28","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.neubiorev.2010.04.001","volume":"34","author":"I Klinkenberg","year":"2010","unstructured":"Klinkenberg I, Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci Biobehav Rev. 2010;34:1307\u201350.","journal-title":"Neurosci Biobehav Rev"},{"key":"2256_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nn992","volume":"6","author":"SG Anagnostaras","year":"2003","unstructured":"Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci. 2003;6:51\u20138.","journal-title":"Nat Neurosci"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02256-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02256-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02256-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:09:17Z","timestamp":1774343357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02256-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,4]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2256"],"URL":"https:\/\/doi.org\/10.1038\/s41386-025-02256-3","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,4]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are employees of MapLight Therapeutics, Inc. and declare no other competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}